TH149016B - 2,3-dihydromidazo [1,2-c] quinazoline derivatives (Substituted 2,3-dihydromidazo [1,2-c] quinazoline Derivatives) are useful for Maintain abnormal growth and enlargement And diseases associated with the formation of new blood vessels - Google Patents
2,3-dihydromidazo [1,2-c] quinazoline derivatives (Substituted 2,3-dihydromidazo [1,2-c] quinazoline Derivatives) are useful for Maintain abnormal growth and enlargement And diseases associated with the formation of new blood vesselsInfo
- Publication number
- TH149016B TH149016B TH701006091A TH0701006091A TH149016B TH 149016 B TH149016 B TH 149016B TH 701006091 A TH701006091 A TH 701006091A TH 0701006091 A TH0701006091 A TH 0701006091A TH 149016 B TH149016 B TH 149016B
- Authority
- TH
- Thailand
- Prior art keywords
- dihydromidazo
- quinazoline derivatives
- enlargement
- substituted
- useful
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002159 abnormal effect Effects 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 210000004204 blood vessel Anatomy 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 150000003246 quinazolines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 3
- 239000000126 substance Substances 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 108030003815 Inositol 3-kinases Proteins 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Abstract
การประดิษฐ์นี้เกี่ยวข้องกับปรพกอบตัวใหม่ 2,3-ไดไฮโดรอิมมิดาโซ[1,2-c] ควิดซลีน, องค์ประกอบในทางเภสัชกรรมที่มีสารประกอบดังกล่าว และ การใช้กลุ่มสารประกอบ หรือ องค์ประกอบสำหรับการยับยั้งฟอสโฟทิดิลไอโนซิทอล-3-ไคเนส (P13K) และ การรักษาโรคที่ สัมพันธ์กับฟอสโฟทิดิลไอโนซิทอล-3-ไคเนส (P13K) แอคตีวิตี้, โดยเฉพาะ การรักษาความผิดปกติ ด้านงอกขยายเกินปกติ และ/หรือ ความผิดปกติด้านการก่อเกิดหลอดเลือดใหม่, ในรูปสารเดี่ยว หรือ ในการรวมกันกับองค์ประกอบออกฤทธิ์ตัวอื่น This invention relates to a new body. 2,3-dihydroimmidazo [1,2-c] quidzoline, a pharmaceutical constituent with such compounds and the use of a group of compounds or elements for phosphotidid inhibition. Inositol-3-kinase (P13K) and the treatment of It is associated with phosphotidyl inositol-3-kinase (P13K) activity, especially in the treatment of disorders. Excessive proliferation and / or angiogenesis, in single substance or in combination with other active ingredients.
Claims (1)
Publications (5)
| Publication Number | Publication Date |
|---|---|
| TH701006091A TH701006091A (en) | |
| TH149016A TH149016A (en) | 2016-04-26 |
| TH149016B true TH149016B (en) | 2016-04-26 |
| TH0701006091B TH0701006091B (en) | 2016-04-26 |
| TH85706B TH85706B (en) | 2021-12-07 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
| RU2498988C2 (en) | Protein tyrosine kinase activity inhibitors | |
| UA103272C2 (en) | 2-AMINO-5,5-DIFLUOR-5,6-DIHYDRO-4H-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS$ 2-AMINO-5,5-DIFLUOR-5,6-DIHYDRO-4H-OXAZINES AS BACE1 AND/OR INHIBITORS OR BACE2 | |
| MX2008013836A (en) | 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
| EA200900152A1 (en) | PYRROLOTRIAZINKINASE INHIBITORS | |
| WO2012007869A3 (en) | N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels | |
| DE60315674D1 (en) | NEW IMIDAZOPYRIDINE AND ITS USE | |
| BRPI0418099A (en) | compounds, pharmaceutical composition, and use of a compound | |
| WO2004087699A3 (en) | Thiazoles useful as inhibitors of protein kinases | |
| WO2004087698A3 (en) | Thiazoles useful as inhibitors of protein kinases | |
| WO2007127635A3 (en) | Diketo-piperazine and piperidine derivatives as antiviral agents | |
| WO2009035997A3 (en) | Benzo-fused heterocycles | |
| EA200971107A1 (en) | CATECHOLAMINE DERIVATIVES, USEFUL FOR THE TREATMENT OF PARKINSON'S Disease | |
| EA200870577A1 (en) | CONDENSED TRICYCLIC SULPHONAMIDE INHIBITORS GAMMA-SECRETASES | |
| EA201200472A1 (en) | SULPHONAMIDES AS AN INHIBITORS OF PROTEINS OF THE BCL-2 FAMILY INTENDED FOR TREATMENT OF CANCER | |
| TN2020000161A1 (en) | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGIuR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
| MY133527A (en) | Isoquinoline derivatives | |
| DE602005018181D1 (en) | MATERIALS AND METHODS FOR TREATING COAGULATION DISORDERS | |
| WO2006026204A3 (en) | Novel gamma-lactams as beta-secretase inhibitors | |
| DE602006009556D1 (en) | CHINOLIN DERIVATIVES FOR THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED ILLNESSES | |
| WO2009119980A3 (en) | Benzophenone thiazole derivatives useful for inhibiting formation of microtubule and method for producing the same | |
| TH149016B (en) | 2,3-dihydromidazo [1,2-c] quinazoline derivatives (Substituted 2,3-dihydromidazo [1,2-c] quinazoline Derivatives) are useful for Maintain abnormal growth and enlargement And diseases associated with the formation of new blood vessels | |
| ATE440835T1 (en) | HETEROCYCLIC UREA DERIVATIVES FOR THE TREATMENT OF PAIN. | |
| WO2024115797A3 (en) | Dihydro-quinazoline, -benzothiazine and -benzoxazine derivatives and use thereof as orexin receptors agonists for treating or preventing neurological diseases | |
| ATE447953T1 (en) | PHARMACEUTICAL COMPOSITIONS FOR TREATING LEISHMANIASIS |